This is a preview of subscription content, log in via an institution to check access.
References
American Cancer Society. Cancer facts and figures 2006. Atlanta (GA): American Cancer Society, 2006
Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351 (27): 2817–26
van’t Veer LJ, Dai H, van der Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415 (6871): 530–6
van der Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347 (25): 1999–2009
Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365 (9460): 671–9
Foekens AJ, Atkins D, Zhang, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol. Epub 2006 Feb 27
Jacquemier J, Ginestier C, Rougement J, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res. 2005; 65 (3): 767–79
Besada V, Diaz M, Becker M, et al. Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance. Proteomics 2006; 6 (3): 1038–48
Rights and permissions
About this article
Cite this article
Improving Treatment of Early Breast Cancer. Pharmaceutical & Diagnostic Innovation 4, 14–16 (2006). https://doi.org/10.1007/BF03257052
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03257052